Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 9/20 | 0.76 |
| ▸ | FLT3 | P36888 | 8/20 | 0.76 |
| ▸ | FLT1 | P17948 | 8/20 | 0.76 |
| ▸ | CSF1R | P07333 | 6/20 | 0.76 |
| ▸ | LCK | P06239 | 6/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.76 |
| ▸ | GSK3B | P49841 | 5/20 | 0.76 |
| ▸ | AURKA | O14965 | 5/20 | 0.76 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.76 |
| ▸ | PLK4 | O00444 | 4/20 | 0.76 |
| ▸ | ABL1 | P00519 | 4/20 | 0.76 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.76 |
| ▸ | FYN | P06241 | 4/20 | 0.76 |
| ▸ | LYN | P07948 | 4/20 | 0.76 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.76 |
| ▸ | MARK3 | P27448 | 4/20 | 0.76 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.76 |
| ▸ | BLK | P51451 | 4/20 | 0.76 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.76 |
| ▸ | NEK2 | P51955 | 4/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473254 | 0.90 | KIT (0.83) | KITFLT3FLT1CSF1RLCK | |
| SCHEMBL4489560 | 0.89 | KDR (0.76) | KITFLT3FLT1CSF1RLCK | |
| SCHEMBL4466621 | 0.88 | KDR (0.79) | KITFLT3FLT1CSF1RLCK | |
| SCHEMBL4478648 | 0.87 | FLT1 (0.79) | KITFLT3FLT1CSF1RLCK | |
| SCHEMBL546436 | 0.86 | KIT (1.00) | KITFLT3FLT1CSF1RLCK | |
| SCHEMBL30055372 | 0.86 | KIT (1.00) | KITFLT3FLT1CSF1RLCK | |
| SCHEMBL4471036 | 0.86 | KIT (0.75) | KITFLT3FLT1CSF1RLCK | |
| Bromide SCHEMBL5436521 | 0.85 | KIT (0.98) | KITFLT3FLT1CSF1RLCK | |
| Hydrochloric Acid SCHEMBL4301600 | 0.85 | KIT (0.98) | KITFLT3FLT1CSF1RLCK | |
| Alcohol SCHEMBL3238965 | 0.85 | FLT1 (0.93) | KITFLT3FLT1CSF1RLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487841-B1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7560552-B2 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KIT 394/4885FLT3 29/4885FLT1 337/4885 |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | ABL1, LCK, ERBB2 | KIT 361/4885FLT3 16/4885FLT1 459/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KIT 394/4885FLT3 29/4885FLT1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.